Patents by Inventor Charles Yang Lin

Charles Yang Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BASE EDITING FOR TREATING HUTCHINSON-GILFORD PROGERIA SYNDROME
    Publication number: 20240173430
    Abstract: The disclosure provides adenosine deaminases that are capable of deaminating adenosine in DNA to treat Hutchin-son-Gilford progeria syndrome (HOPS). The disclosure also provides fusion proteins, guide RNAs and compositions comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA, for example in a LNA gene. In some embodiments, adenosine deaminases provided herein are used to correct a C1824T mutation in LMNA. In some embodiments, the methods and compositions provided herein are used to treat Hutchinson-Gilford progeria syndrome (HGPS).
    Type: Application
    Filed: September 5, 2019
    Publication date: May 30, 2024
    Applicants: The Broad Institute, Inc., Baylor College of Medicine, Vanderbilt University, President and Fellows of Harvard College
    Inventors: David R. Liu, Luke W. Koblan, Jonathan D. Brown, Charles Yang Lin
  • Mechanism of resistance to bet bromodomain inhibitors
    Patent number: 11666580
    Abstract: The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
    Type: Grant
    Filed: August 10, 2016
    Date of Patent: June 6, 2023
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Kornelia Polyak, Shaokun Shu, James E. Bradner, Charles Yang Lin
  • MECHANISM OF RESISTANCE TO BET BROMODOMAIN INHIBITORS
    Publication number: 20200368248
    Abstract: The present disclosure provides combination therapy comprising a BET inhibitor and a protein phosphatase 2A (PP2A) activator, a B-cell lymphoma-2 (Bcl-2) inhibitor, a B-cell lymphoma-extra large (Bcl-xl) inhibitor, a casein kinase 2 (CK2) inhibitor, and/or a mediator complex subunit 1 (MED1) for cancer. The combination therapy is expected to be synergistic in treating the cancer, compared to the monotherapy. Methods for identifying a subject having a cancer that is resistant to or at risk of developing resistance to bromodomain and extra terminal (BET) inhibitor therapy are also provided.
    Type: Application
    Filed: August 10, 2016
    Publication date: November 26, 2020
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Kornelia Polyak, Shaokun Shu, James E. Bradner, Charles Yang Lin